These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23633399)

  • 21. Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer.
    Innominato PF; Spiegel D; Ulusakarya A; Giacchetti S; Bjarnason GA; Lévi F; Palesh O
    Sleep Med; 2015 Mar; 16(3):391-8. PubMed ID: 25678361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Vaidyanathan G; Groman A; Wilding G; Fakih MG
    Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
    Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
    Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
    Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
    Lévi F; Zidani R; Misset JL
    Lancet; 1997 Sep; 350(9079):681-6. PubMed ID: 9291901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
    Ortiz-Tudela E; Iurisci I; Beau J; Karaboue A; Moreau T; Rol MA; Madrid JA; Lévi F; Innominato PF
    Int J Cancer; 2014 Jun; 134(11):2717-25. PubMed ID: 24510611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
    Berretta M; Bearz A; Frustaci S; Talamini R; Lombardi D; Fratino L; Lleshi A; Bonanno S; Spartà D; Palmucci S; Berretta S; Tirelli U
    J Chemother; 2008 Aug; 20(4):503-8. PubMed ID: 18676233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
    Giacchetti S; Dugué PA; Innominato PF; Bjarnason GA; Focan C; Garufi C; Tumolo S; Coudert B; Iacobelli S; Smaaland R; Tampellini M; Adam R; Moreau T; Lévi F;
    Ann Oncol; 2012 Dec; 23(12):3110-3116. PubMed ID: 22745214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.